BONESUPPORT HOLDING AB (DE:2B4)
FRANKFURT:2B4
Want to see DE:2B4 full AI Analyst Report?
2B4 Stock Chart & Stats
€17.08
-€0.24(-0.69%)
At close: 4:00 PM EST
€17.08
-€0.24(-0.69%)
Day’s Range― - ―
52-Week Range€15.50 - €30.66
Previous CloseN/A
Volume165.00
Average Volume (3M)55.00
Market Cap
€1.58B
Enterprise Value€17.35B
Total Cash (Recent Filing)€377.99M
Total Debt (Recent Filing)€15.88M
Price to Earnings (P/E)87.1
Beta0.22
Next Earnings
Apr 22, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding65,859,190
10 Day Avg. Volume69
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.44
Revenue Forecast (FY)€139.62M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year revenue expansion reflects durable product adoption across orthopedic and trauma procedures, validating CERAMENT's product-market fit. This scale supports continued geographic expansion and provides a stable base for reinvesting in commercialization and clinical evidence generation.
Gross Margin SustainabilityVery high and persistent gross margins indicate structurally advantaged product economics (low COGS for implantable/ injectable biomaterial). High gross margins underwrite operating leverage, strong FCF potential, and provide buffer against коммерcial cost increases or modest pricing pressure.
Balance Sheet & Cash GenerationConservative financing and materially positive free cash flow demonstrate financial flexibility to fund commercial expansion, clinical studies, and regulatory processes without near‑term refinancing risk. Strong cash conversion improves resilience through uneven adoption or reimbursement cycles.
Bears Say
Regulatory Timing Risk (CERAMENT V)Reclassification to a De Novo pathway extends approval timing and increases regulatory uncertainty, delaying anticipated U.S. sales contribution. This compresses upside in near‑term guidance and raises the risk that incremental R&D and submission costs weigh on margins before revenue ramps.
Rising Commercial & Distributor CostsHigher selling, staffing and distributor fees are structural as the company scales into new accounts and geographies. Sustained elevated commercial costs can erode operating leverage and require higher sales growth to maintain margins, reducing the durability of recent margin expansion.
Geographic/Market Access Headwinds (Germany)Regulatory and reimbursement reforms in a key European market can permanently alter procedure volumes and hospital purchasing behavior. Prolonged weakness in Germany may constrain regional growth, force reallocation of commercial resources, and delay breakeven in slower markets.
BONESUPPORT HOLDING AB News
2B4 FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was €15.50 and its highest was €30.66 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is €1.58B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Apr 22, 2026 which is in 4 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Feb 24, 2026. The company reported €0.062 earnings per share for the quarter, missing the consensus estimate of €0.081 by -€0.019.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.09.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of €0.062 in its last earnings report, missing expectations of €0.081. Following the earnings report the stock price went up 7.38%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in DE:2B4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
2B4 Company Deck
2B4 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).View all DE:2B4 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---